
    
      This study will be a Phase 2, double-blind, randomized, placebo-controlled study in up to 72
      participants. Participants will be randomized in a 2:1 ratio to either IONIS-AGT-LRX or
      matching placebo and receive a once-weekly SC treatment. The length of participation in the
      study will be approximately 29 weeks, which includes an up to 4-week screening period, a
      12-week treatment period, and a 13-week post-treatment period.
    
  